Patrys Ltd has released a press release.
PAT-DX1 Conjugated to Nanoparticles, Targets Tumors
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Patrys
- PAT-DX1 Active in Pre-clinical Cancer Models
- Appendix 4E and 2017 Annual Report
- Appendix 4C - Quarterly - 30 June 2017
- Patrys Deoxymab 3E10 patent granted in the U.S.
- PAB Licences Deoxymab 3E10 - nanoparticle IP from Yale
Later from Patrys
- US Patent Granted for Preclinical Candidate PAT-LM1
- PAB and Garvan Institute of Medical Research Awarded Grant
- Appendix 4C - Quarterly - 30 September 2017
- Collaboration with WEHI
- PAT-DX1 is synergistic with PARP inhibitor
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys